Possible treatment for Charcot-Marie-Tooth disease (CMT1A) discovered

idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Grafik: idw-Logo

idw - Informationsdienst


09.08.2018 16:47

Possible treatment for Charcot-Marie-Tooth disease (CMT1A) discovered

Stefan Weller Stabsstelle Unternehmenskommunikation, Presse- und Öffentlichkeitsarbeit
Universitätsmedizin Göttingen - Georg-August-Universität

    The dietary supplement Lecithin improves the myelination of diseased Schwann cells. Publication in Nature Communications.

    (mpi/umg) Charcot-Marie-Tooth (CMT) disease is the most common hereditary neuropathy and affects more than two million people worldwide. Alone in Germany, at least 30.000 people suffer from Charcot-Marie-Tooth neuropathy which belongs to the class of rare disease. In a close collaboration at the Göttingen campus, researchers at the Max-Planck-Institute for Experimental Medicine and the University Medical Center of Göttingen now hope to use lecithin, a harmless dietary supple-ment to treat the incurable illness. The results of the study were published in „Nature Communications“.

    Due to a genetic defect that causes a duplication of the PMP22 gene, patients with a Charcot-Marie-Tooth disease develop a slowly progressive impairment of their peripheral nerves (CMT1A). Early symptoms, like walking difficulties or deformed feet can already occur during childhood. Later, muscle muscle weekness in legs and arms occur, but also numbness, prickling or pain. In rare cases, patients may be forced to use wheelchairs.

    The axons, projections of nerve cells in the peripheral nervous system, are sur-rounded by supporting cells over their entire length. These Schwann cells produce a fatty layer, the myelin, around the axons which allows for a faster transfer of electric signals. Using a transgenic rat model of CMT1A, scientists at the Max-Planck-Institute for Experimental Medicine and the University Medical Center in Göttingen, as well as neuroscientists from Leipzig, Würzburg, Heidelberg and Aachen now discovered that diseased Schwann cells show a decreased fat metabolism during their development which causes the impaired myelination. “The production of myelin is extremely laborious for Schwann cells. A disruption, like the one the Charcot-Marie-Tooth disease causes, leaves the nerve fibers without myelin, which limits their functionality”, explains the first author of the study, Robert Fledrich, Max-Planck-Institute of Experimental Medicine and Institute of Anatomy of Leipzig University Medicine.

    Schwann cells use Phospholipids for the myelination
    Using lecithin, the reduced fat production of Schwann cells may be circumvented and the disturbed myelination in Charcot-Marie-Tooth disease thus be improved. Lecithin is produced from soy or yolk and consists of phospholipids. It is a harmless dietary supplement and the main ingredient of myelin. Initially, the scientists were able to show that the phospholipids in genetically modified rats were absorbed by the Schwann cells and used for the production of myelin.

    Therapy studies with diseased rats that were given lecithin in various doses not only showed that a treatment with phospholipids promotes the myelination. “It significantly eases the course of the disease regardless of the start of the therapy”, explains Ruth Stassart, a neuropathologist from the Departement of Neuropathology of Leipzig University Medicine and Max-Planck Institute for Experi-mental Medicine, who co-lead the study. “The promising data from the animal testing and especially the already proven compatibility of with humans, promote Lecithin as a therapeutic agent for the Charcot-Marie-Tooth disease as well as possibly for similar demyelinating diseases”, adds Michael Sereda, a neurologist at the Department of Clinical Neurophysiology at the University Medical Center Göt-tingen and group leader at the Max-Planck-Institute for Experimental Medicine who co-directed the study together with Ruth Stassart.

    The participating neurologists and neuroscientists now plan to use these findings from animal models in order to help patients by initiating clinical trials.

    Wissenschaftliche Ansprechpartner:

    Prof. Dr. med. Michael W. Sereda
    Max-Planck-Institute of Experimental Medicine
    Research Group “Molecular and Translational Neurology”
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen

    University Medical Center Göttingen – University of Göttingen
    Department of Clinical Neurophysiology
    Robert-Koch-Str. 40, 37075 Göttingen
    Phone: +49-551-3899-760/732 oder +49-551-39-9662
    Email: sereda@em.mpg.de
    www.cmt-net.de, www.neurologie.uni-goettingen.de, www.em.mpg.de

    Dr. rer. nat. Robert Fledrich
    Institute of Anatomy – Leipzig University Medicine
    Liebigstr, 13, 04103 Leipzig

    Max-Planck-Institute of Experimental Medicine
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen
    Phone: +49-341-9715037
    Email: fledrich@em.mpg.de

    Dr. med. Ruth M. Stassart
    Max-Planck-Institute of Experimental Medicine
    Research Group “Remyelination and Nerve Repair”
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen

    Abteilung für Neuropathologie, Department für Diagnostik
    Leipzig University Medicine
    Liebigstr. 26, 04103 Leipzig
    Email: stassart@em.mpg.de

    Prof. Klaus-Armin Nave, PhD
    Max-Planck-Institute of Experimental Medicine
    Department of Neurogenetics
    Hermann-Rein-Str. 3, 37075 Göttingen
    Email: nave@em.mpg.de
    Phone: +49-551-3899-760


    "Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy", R. Fledrich, T. Abdelaal, L. Rasch, V. Bansal, V. Schütza, B. Brügger, C. Lüchtenborg, T. Prukop, J. Stenzel, R.U. Rahman, D. Hermes, D. E-wers, W. Möbius, T. Ruhwedel, I. Katona, J. Weis, D. Klein, R. Martini, W. Brück, W.C. Müller, S. Bonn, I. Bechmann, K.A. Nave, R.M. Stassart & M.W. Sereda; Nature Communications; 2. August 2018 (DOI: 10.1038/s41467-018-05420-0)

    Merkmale dieser Pressemitteilung:
    Biologie, Medizin
    Forschungsergebnisse, Forschungsprojekte


    Die Suche / Erweiterte Suche im idw-Archiv

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.


    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).


    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.


    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).

    Cookies optimieren die Bereitstellung unserer Dienste. Durch das Weitersurfen auf idw-online.de erklären Sie sich mit der Verwendung von Cookies einverstanden. Datenschutzerklärung